Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
Huang DQ, Noureddin N, Ajmera V, Amangurbanova M, Bettencourt R, Truong E, Gidener T, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Yoneda M, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Allen AM, Noureddin M, Loomba R.
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):829-836. doi: 10.1016/S2468-1253(23)00157-7. Epub 2023 Jul 4.
Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.
Salminen P, Grönroos S, Helmiö M, Hurme S, Juuti A, Juusela R, Peromaa-Haavisto P, Leivonen M, Nuutila P, Ovaska J.
JAMA Surg. 2022 Aug 1;157(8):656-666. doi: 10.1001/jamasurg.2022.2229.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines.
Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24.
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH.
BMC Public Health. 2009 Mar 25;9:88. doi: 10.1186/1471-2458-9-88.
Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.
Liu BD, Udemba SC, Liang K, Tarabichi Y, Hill H, Fass R, Song G.
Gut. 2024 Jan 5;73(2):246-254. doi: 10.1136/gutjnl-2023-329651.
Diabetic autonomic neuropathy.
Vinik AI, Maser RE, Mitchell BD, Freeman R.
Diabetes Care. 2003 May;26(5):1553-79. doi: 10.2337/diacare.26.5.1553.
The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Wu HD, Zhang JJ, Zhou BJ.
Clin Transl Oncol. 2021 Feb;23(2):275-282. doi: 10.1007/s12094-020-02415-6. Epub 2020 Jun 7.
A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists.
Wu Q, Zeng Y, Liu Y, Teng F, Zhou T, Guo M, Jiang Z, Xu Y.
Front Endocrinol (Lausanne). 2025 Mar 20;16:1532587. doi: 10.3389/fendo.2025.1532587. eCollection 2025.
White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources.
Acosta A, Streett S, Kroh MD, Cheskin LJ, Saunders KH, Kurian M, Schofield M, Barlow SE, Aronne L.
Clin Gastroenterol Hepatol. 2017 May;15(5):631-649.e10. doi: 10.1016/j.cgh.2016.10.023. Epub 2017 Feb 27.
INFLUENCE OF URSODEOXYCHOLIC ACID ON THE CHOLECYSTOKININ LEVELS IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE AND TYPE 2 DIABETES MELLITUS.
Sirchak Y, Derbak M, Stan M, Petrichko O.
Georgian Med News. 2021 Mar;(312):67-71.
